



## **REGENXBIO Announces Presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference**

August 10, 2022 07:05 AM EDT

ROCKVILLE, Md., Aug. 10, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17th, 2022:

**Panel: Unique Delivery Technology Platforms for Better Compliance and Efficacy**

**Date:** Wednesday, August 17<sup>th</sup>, 2022

**Time:** 11:00 a.m. ET

A live webcast of the panel can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

### **About REGENXBIO Inc.**

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

**Contacts:**

Dana Cormack  
Corporate Communications  
[dcormack@regenxbio.com](mailto:dcormack@regenxbio.com)

**Investors:**

Chris Brinzey, ICR Westwicke  
339-970-2843  
[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-the-hc-wainwright-2nd-annual-ophthalmology-virtual-conference-301603169.html>

SOURCE REGENXBIO Inc.